Orange Book product · Generic (ANDA)
PAZOPANIB HYDROCHLORIDE
PAZOPANIB HYDROCHLORIDE
At a glance
Sep 04, 2025
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 04, 2025
10 mo ago
Exclusivity ends · CGT
FDA marketing exclusivity
May 06, 2026
1 mo ago
Today
Pharmaceutical detail
Active ingredient
PAZOPANIB HYDROCHLORIDE
Strength
EQ 400MG BASE
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
ANDA 219922
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of PAZOPANIB HYDROCHLORIDE
- 2009VOTRIENTBrand (NDA)
NDA 022465 · NOVARTIS
- 2024PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 219034 · EUGIA PHARMA
- 2024PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 218231 · NOVUGEN
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 217713 · APOTEX
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 215837 · SUN PHARM
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 217517 · TEVA PHARMS INC
Marketing exclusivity (1)
- CGTFDA marketing exclusivity
May 06, 2026
1 mo ago
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
